Elan completes $1.5 billion deal with Johnson & Johnson

Elan Corporation Plc has reached an agreement with Johnson & Johnson that will give the US multinational an 18.4% stake in the company as well as controlling interest in a new unit that will hold many of Elan’s assets in Alzheimer’s disease.